Cyberonics panel date finalized
This article was originally published in The Gray Sheet
Executive Summary
VNS vagus nerve stimulation therapy for depression will go before FDA's Neurological Devices Panel June 15, CDRH says, confirming company's announcement (1"The Gray Sheet" April 5, 2004, p. 8). A PMA supplement covers adjunctive treatment of chronic or recurrent depression for patients resistant to antidepressants...
You may also be interested in...
Cyberonics VNS Depression Treatment Panel Review Tentatively Set For June
FDA's Neurological Devices Advisory Panel will review a PMA supplement for Cyberonics' VNS Therapy depression indication June 15, the firm says
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.